NPM1P21: A Drug Target / Disease Biomarker (G100129237)
NPM1P21: A Drug Target / Disease Biomarker
NPM1P21 is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and muscle. It is a key regulator of the cellular signaling pathway known as the TGF-β pathway, which is involved in the development and maintenance of tissues and organs, as well as in the regulation of cellular processes such as cell growth, differentiation, and survival.
Recent studies have identified NPM1P21 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions makes it an attractive target for researchers to explore new therapeutic approaches.
One of the key reasons for the potential of NPM1P21 as a drug target is its involvement in the TGF-β pathway. The TGF-β pathway is a complex signaling pathway that plays a crucial role in the development and maintenance of tissues and organs, as well as in the regulation of cellular processes such as cell growth, differentiation, and survival. Mutations in the TGF-β pathway have been linked to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
NPM1P21 is a key regulator of the TGF-β pathway, and its involvement in this pathway makes it a potential drug target.
The NPM1P21 protein is a key regulator of the TGF-β pathway. It is a 21-kDa protein that is expressed in various tissues throughout the body, including the brain, pancreas, and muscle. NPM1P21 functions as a negative regulator of the TGF-β pathway, which is involved in the development and maintenance of tissues and organs, as well as in the regulation of cellular processes such as cell growth, differentiation, and survival.
NPM1P21 functions as a negative regulator of the TGF-β pathway by preventing the activation of TGF-β signaling pathways. This is done by the NPM1P21 protein, which is involved in the regulation of the activities of several transcription factors that are involved in the TGF-β pathway. These transcription factors include SMAD1, SMAD4, and TGF-β1.
The NPM1P21 protein is involved in the regulation of several cellular processes that are critical for the development and maintenance of tissues and organs. For example, NPM1P21 is involved in the regulation of cell proliferation, cell differentiation, and cell survival. It is also involved in the regulation of cellular processes such as cell migration and the formation of tissues and organs.
In addition to its involvement in the TGF-β pathway, NPM1P21 is also involved in the regulation of several other cellular processes that are critical for the development and maintenance of tissues and organs. For example, it is involved in the regulation of the production of extracellular matrix (ECM) components, such as collagen and elastin, which are important for tissue structure and function. It is also involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin, which are important for cellular signaling.
The potential benefits of targeting NPM1P21 as a drug target are significant. If NPM1P21 were to be successfully targeted, it could potentially lead to the development of new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
Targeting NPM1P21 as a drug target could also have the potential to improve the treatment outcomes for these diseases. For example, in the case of cancer, targeting NPM1P21 as a drug target could potentially lead to the development of new treatments that specifically target this protein and result in a more effective and less
Protein Name: Nucleophosmin 1 Pseudogene 21
The "NPM1P21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPM1P21 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NPM1P22 | NPM1P25 | NPM1P27 | NPM1P28 | NPM1P35 | NPM1P42 | NPM1P47 | NPM1P48 | NPM2 | NPM3 | NPNT | NPPA | NPPA-AS1 | NPPB | NPPC | NPR1 | NPR2 | NPR3 | NPRL2 | NPRL3 | NPS | NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS
